Table 1

Performance of HPV DNAdetection using HC2, LA and anal cytology for identification of HGAIN lesions results among HIV-infected men who have sex with men

Sensitivity (95% CI)Specificity (95% CI)PPV (95% CI)NPV (95% CI)PLR (95% CI)NLR (95% CI)Area under ROC curve (95% CI)Youden’s index
HPV DNA detection
HC290.0% (68.3 to 98.8)58.4% (50.2 to 66.3)22.0% (13.6 to 32.5)97.8% (92.4 to 99.7)2.2 (1.7 to 2.7)0.2 (0.5 to 0.6)0.74 (0.66 to 0.82)0.484
LA (oncogenic HPV genotypes)95.0% (75.1 to 99.9)27.3% (20.4 to 35.0)14.5% (9.0 to 21.7)97.7% (87.7 to 99.9)1.3 (1.1 to 1.5)0.2 (0.0 to 1.3)0.61 (0.55 to 0.67)0.223
LA HPV1670.0% (45.7 to 88.1)76.6% (69.1 to 83.1)28.0% (16.2 to 42.5)95.2% (89.8 to 98.2)3.0 (2.0 to 4.5)0.4 (0.2 to 0.8)0.73 (0.63 to 0.84)0.466
LA HPV1825.0% (8.7 to 49.1)91.6% (86.0 to 95.4)27.8% (9.7 to 53.5)90.4% (84.6 to 94.5)3.0 (1.2 to 7.4)0.8 (0.6 to 1.1)0.58 (0.48 to 0.68)0.166
LA HPV16/18*90.0% (68.3 to 98.8)72.7% (65.0 to 79.6)30.0% (18.8 to 43.2)98.2% (93.8 to 99.8)3.3 (2.4 to 4.4)0.1 (0.0 to 0.5)0.81 (0.74 to 0.89)0.627
LA HPV6 and/or 16 and/or 1895.0% (75.1 to 99.9)61.0% (52.9 to 68.8)24.1% (15.1 to 35.0)98.9% (94.3 to 100)2.4 (1.9 to 3.0)0.1 (0.0 to 0.6)0.78 (0.72 to 0.84)0.560
LA HPV genotypes frequently identified in anal cancer (HPV16, 18, 33, 35, 58)90.0% (68.3 to 98.8)59.1% (50.9 to 66.9)22.2% (13.7 to 32.8)97.8% (92.4 to 99.7)2.2 (1.7 to 2.8)0.2 (0.5 to 0.6)0.745 (0.67 to 0.82)0.491
Anal cytology
Abnormal95.0% (75.1 to 99.9)56.4% (48.0 to 64.5)22.6% (14.2 to 33.0)98.8% (93.6 to 100.0)2.2 (1.8 to 2.7)0.1 (0.0 to 0.6)0.76 (0.69 to 0.82)0.514
HSIL45.0% (23.1 to 68.5)96.0% (91.4 to 98.5)60.0% (32.3 to 83.7)92.9% (87.6 to 96.4)11.2 (4.4 to 28.1)0.6 (0.4 to 0.9)0.70 (0.59 to 0.82)0.410
HPV DNA detection and anal cytology
HC2 and abnormal85.0% (62.1 to 96.8)72.5% (64.6 to 79.5)29.3% (18.1 to 42.7)97.3% (92.3 to 99.4)3.1 (2.3 to 4.3)0.2 (0.1 to 0.6)0.79 (0.70 to 0.88)0.575
HPV16/18 and abnormal85.0% (62.1 to 96.8)81.9% (74.7 to 87.7)38.6% (24.4 to 54.5)97.6% (93.1 to 99.5)4.7 (3.2 to 6.9)0.2 (0.1 to 0.5)0.83 (0.75 to 0.92)0.669
HC2 and HSIL45.0% (23.1 to 68.5)96.0% (91.4 to 98.5)60.0% (32.3 to 83.7)92.9% (87.6 to 96.4)11.2 (4.5 to 28.1)0.6 (0.4 to 0.9)0.71 (0.59 to 0.82)0.410
HPV16/18 and HSIL45.0% (23.1 to 68.5)97.3% (93.3 to 99.3)69.2% (38.6 to 90.9)92.9% (87.7 to 96.4)16.8 (5.7 to 49.4)0.6 (0.4 to 0.8)0.71 (0.60 to 0.82)0.423
  • Abnormal: ASC-US or ASC-H or LSIL.

  • Table created by the authors.

  • *Presence of HPV16, HPV18 or both HPV genotypes.

  • ASC-H, atypical squamous cells cannot exclude HSIL; ASC-US, atypical squamous cells of undetermined significance; HC2, Hybrid Capture 2 HPV DNA test; HGAIN, high-grade anal intraepithelial neoplasia; HPV, human papillomavirus; HSIL, high-grade squamous intraepithelial lesion; LA, Linear Array Genotyping Test; LSIL, low-grade squamous intraepithelial lesion; NLR, negative likelihood ratio; NPV, negative predictive value; PLR, positive likelihood ratio; PPV, positive predictive value; ROC, receiver operating characteristic.